Evidence map›Paper›PMID 34816022›Full record

ArticleClinical and translational radiation oncology2022

High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.

Maud le Guyader, Daniel Lam Cham Kee, Brice Thamphya, Renaud Schiappa, Mathieu Gautier, Marie-Eve Chand-Fouche, Jean-Michel Hannoun-Levi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Radiochemotherapy and interstitial brachytherapy for cervical cancer: clinical results and patient-reported outcome measures.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Maud le GuyaderDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Daniel Lam Cham KeeDepartment of Radiation Oncology, Pôle Santé République, Clermont-Ferrand, France.
Brice ThamphyaDepartment of Statistics, Antoine Lacassagne Cancer Center, University of Côte d'Azur, Nice, France.
Renaud SchiappaDepartment of Statistics, Antoine Lacassagne Cancer Center, University of Côte d'Azur, Nice, France.
Mathieu GautierDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Marie-Eve Chand-FoucheDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Jean-Michel Hannoun-LeviDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Centre Antoine Lacassagne · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBrachytherapy (BT) boost after radio-chemotherapy (RCT) is a standard of care in the management of locally advanced cervical cancer (LACC). As there is no consensus on high-dose-rate (HDR) BT fractionation schemes, our aim was to report the oncological outcome and toxicity profile of four different schemes using twice-a-day (BID) HDR-BT. PATIENTS AND

methodsThis was an observational, retrospective, single institution study for patients with LACC receiving a HDR-BT boost. The latter was performed with a single implant and single imaging done on day 1. The different fractionation schemes were: 7 Gy + 4x3.5 Gy (group 1); 7 Gy + 4x4.5 Gy (group 2); 3x7Gy (group 3) and 3x8Gy (group 4). Local (LFS), nodal (NFS) and metastatic (MFS) recurrence-free survival as well as progression-free survival (PFS) and overall survival (OS) were analyzed. Acute (≤6 months) and late toxicities (>6 months) were reported.

resultsFrom 2007 to 2018, 191 patients were included. Median follow-up was 57 months [45-132] and median EQD2

conclusionBi-fractionated HDR-BT boost seems feasible with good oncological outcome and slightly more toxicity after dose escalation.

Indexed as

BED, biologically effective doseBID, twice-a-dayBMI, body-mass indexBrachytherapyBT, brachytherapyCervical cancerCTCAE, common terminology criteria for adverse eventsCT, computerized tomographyCTV, clinical target volumeEBRT, external beam radiotherapyEMBRACE, image guided intensity modulated External beam radiochemotherapy and MRI based Adaptative BRAchytherapy in locally advanced CErvical cancerEQD2Gy, equivalent dose at 2 GyESTRO, European Society for Radiotherapy and OncologyFIGO, International Federation of Gynecology and ObstetricsFractionation schemeGEC, groupe européen de curiethérapieGTV, gross tumor volumeHDR, high-dose-rateHigh-dose-rateHIV, human immunodeficiency virusHR, high-riskICRU, International Commission on Radiation Units and measurementsIGABT, image-guided adaptative brachytherapyIMRT, intensity modulated radiotherapyIR, intermediate-riskLACC, locally advanced cervical cancerLDR, low-dose-rateLFS, local recurrence-free survivalLQ, linear quadraticMFS, metastatic recurrence-free survivalMFU, median follow upMRI, magnetic resonance imagingNA, not availableNCI, national cancer instituteNFS, nodal recurrence-free survivalOAR, organs at riskOS, overall survivalOTT, overall treatment timePDR, pulsed-dose-ratePET, positron emission tomographyPFS, progression-free survivalpt, patientpts, patientsPTV, planning target volumeRCT, radio-chemotherapySCC, squamous cell cancerSEER, surveillance, epidemiology and end results

Identifiers

PMID34816022
PMCPMC8592834
OpenAlexW3211620168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.